Increased <i>Huwe1</i> after induction of Sox2 in mouse ES cells. by Yen-Fu Cheng (5819855)

“…<i>Atoh1</i> expression increased with <i>Sox2</i> at low levels but decreased at higher <i>Sox2</i> level. …”

Patient and family perceptions of signs and symptoms of acute deterioration (ordered by most to least frequently selected as “absolutely”). by Lisa Thiele (6468056)

Subjects:

Local consumer escalation process (adapted from Local Health Network (CALHN) procedure 2019) [16]. by Lisa Thiele (6468056)

Subjects:

Tunel detection of myocardial apoptosis. by Qingqing Hao (5464070)

Subjects:

Cardiomyocyte apoptosis rate in the CCM group. by Qingqing Hao (5464070)

Subjects:

The primer sequences of the genes used in the RT-PCR. by Qingqing Hao (5464070)

Subjects:

Fig 2 - by Qingqing Hao (5464070)

Subjects:

Cardiomyocyte apoptosis rate in the Sham group. by Qingqing Hao (5464070)

Subjects:

Cardiomyocyte apoptosis rate in the three groups. by Qingqing Hao (5464070)

Subjects:

Changes in mRNA expression of Caspase-3, ALDH2, Bcl-2, Bax and Bcl-2/Bax in three groups. by Qingqing Hao (5464070)

Subjects:

Apoptosis ratio in three groups. by Qingqing Hao (5464070)

Subjects:

Comparison of myocardial LC3 immunofluorescence staining of three groups (×400, scale bar = 10μm). by Qingqing Hao (5464070)

Subjects:

S1 File - by Qingqing Hao (5464070)

Subjects:

Cardiomyocyte apoptosis rate in the HF group. by Qingqing Hao (5464070)

Subjects:

Comparison of Beclin1, P62 and LC3B(II/I) protein expression levels in three groups. by Qingqing Hao (5464070)

Subjects:

Fig 3 - by Qingqing Hao (5464070)

Subjects:

Flowchart of the screening process. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the AMSTAR-2 assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Characteristics of included reviews. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the PRISMA assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”